SRPT — Sarepta Therapeutics, Inc.

Summary of Sarepta Therapeutics Q3 2025 Earnings Call

1. Key Financial Results and Metrics

• Total Revenues: $399 million, comprising $370 million in net product revenues and $29 million from collaborations and royalties.
• Net Product Revenue Breakdown:
  • ELEVIDYS: $131 million
  • PMOs (exon skipping therapies): $239 million
• Operating Loss: $103 million (GAAP), $36 million (non-GAAP), with adjustments indicating an underlying profit of $37 million (GAAP) and $54 million (non-GAAP).
• Cash Position: Increased from $850 million to $865 million, with Q3 being cash flow positive.
• R&D Expenses: $219 million (GAAP), flat compared to the prior year; restructuring costs of $41 million were incurred due to a reduction in force and pipeline reprioritization.

2. Strategic Updates and Business Highlights

• Completion of ESSENCE Trial: The confirmatory study for VYONDYS and AMONDYS was completed, although it did not meet statistical significance on the primary endpoint. However, post-hoc analyses indicated a 30% reduction in disease progression in non-COVID-impacted patients.
• ELEVIDYS Label Update: A black box warning for acute liver injury (ALI) and acute liver failure (ALF) has been agreed upon with the FDA, and non-ambulatory patients will be removed from the indication.
• SiRNA Pipeline: Progress is being made in siRNA programs for DM1 and FSHD, with initial data expected in early 2026.
• Real-World Evidence: Continued to support the efficacy of PMOs, showing significant delays in disease progression for treated patients.

3. Forward Guidance and Outlook

• ELEVIDYS Revenue Guidance: The company maintains a floor revenue estimate of $500 million for the ambulatory population, despite near-term disruptions.
• Q4 Expectations: Anticipated flat to slightly down infusion volumes due to seasonal dynamics and the impact of the recent pause in shipments.
• Long-Term Outlook: Confident in the long-term potential of ELEVIDYS and PMOs, with plans to engage with the FDA regarding transitioning from accelerated to traditional approval.

4. Bad News, Challenges, or Points of Concern

• COVID Impact: The ESSENCE trial results were confounded by the COVID pandemic, leading to missed doses and operational challenges that affected patient outcomes.
• Regulatory Risks: There are concerns regarding the FDA's potential reaction to the ESSENCE trial results, particularly in light of recent leadership changes at the agency.
• Market Disruptions: The pause in shipments to the non-ambulatory population caused significant downstream disruptions, affecting patient access and new patient identification efforts.
• Competitive Pressures: Emerging therapies in the gene therapy space could impact ELEVIDYS demand, although the company is not currently providing detailed guidance on this front.

5. Notable Q&A Insights

• FDA Interaction: The company plans to submit a meeting request to the FDA by year-end to discuss the ESSENCE trial data and potential pathways for traditional approval.
• Data Expectations: Analysts inquired about the significance of the p-value of 0.09 in the ESSENCE trial, with management expressing confidence that the FDA may accept this in the context of rare diseases.
• Sirolimus Prophylaxis: There is anecdotal evidence that some prescribers are using sirolimus prophylactically for ambulatory patients, but systematic data is lacking.
• Patient Enrollment: There is a noted lag in patient enrollment due to the complexities of the infusion process, but early trends indicate a positive outlook for future enrollment and revenue growth.

This summary encapsulates the key points from Sarepta's Q3 2025 earnings call, highlighting financial performance, strategic initiatives, challenges, and insights from the Q&A session.